SI2481429T1 - MMP-14 specific cleavage sequence - Google Patents
MMP-14 specific cleavage sequence Download PDFInfo
- Publication number
- SI2481429T1 SI2481429T1 SI200831959T SI200831959T SI2481429T1 SI 2481429 T1 SI2481429 T1 SI 2481429T1 SI 200831959 T SI200831959 T SI 200831959T SI 200831959 T SI200831959 T SI 200831959T SI 2481429 T1 SI2481429 T1 SI 2481429T1
- Authority
- SI
- Slovenia
- Prior art keywords
- mmp
- peptide
- hof
- cit
- tyr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0707034.5A GB0707034D0 (en) | 2007-04-12 | 2007-04-12 | Compounds |
| EP12160565.3A EP2481429B1 (en) | 2007-04-12 | 2008-03-27 | MMP-14 specific cleavage sequence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2481429T1 true SI2481429T1 (en) | 2018-08-31 |
Family
ID=38116587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200831959T SI2481429T1 (en) | 2007-04-12 | 2008-03-27 | MMP-14 specific cleavage sequence |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8691751B2 (enExample) |
| EP (4) | EP2134372B1 (enExample) |
| JP (4) | JP5537413B2 (enExample) |
| CY (1) | CY1120368T1 (enExample) |
| DK (3) | DK2134372T3 (enExample) |
| ES (3) | ES2573228T3 (enExample) |
| GB (1) | GB0707034D0 (enExample) |
| HK (1) | HK1258466A1 (enExample) |
| HR (1) | HRP20181043T1 (enExample) |
| HU (3) | HUE027528T2 (enExample) |
| LT (1) | LT2481429T (enExample) |
| PL (3) | PL2481429T3 (enExample) |
| PT (1) | PT2481429T (enExample) |
| SI (1) | SI2481429T1 (enExample) |
| TR (1) | TR201807811T4 (enExample) |
| WO (1) | WO2008125800A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0707034D0 (en) | 2007-04-12 | 2007-05-23 | St Andrews The | Compounds |
| GB0819287D0 (en) * | 2008-10-22 | 2008-11-26 | Univ Bradford | Compounds |
| GB2516882A (en) * | 2013-08-02 | 2015-02-11 | Univ Bradford | Tumour-targeted theranostic |
| US9169337B2 (en) | 2014-03-12 | 2015-10-27 | Chevron Phillips Chemical Company Lp | Polymers with improved ESCR for blow molding applications |
| NZ731185A (en) * | 2014-10-29 | 2024-03-22 | Bicyclerd Ltd | Bicyclic peptide ligands specific for mt1-mmp |
| GB2545169B (en) * | 2015-12-01 | 2019-10-09 | Ellipses Pharma Ltd | Taxane Prodrug Comprising A Membrane Type Matrix Metalloproteinase Cleavage Site |
| AU2018297614B2 (en) | 2017-07-07 | 2024-04-04 | Katholieke Universiteit Leuven | Treatment of avascular or hypovascular micro-tumors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4583601A (en) * | 2000-03-15 | 2001-09-24 | Du Pont Pharm Co | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
| GB0018240D0 (en) * | 2000-07-25 | 2000-09-13 | Pharmacia & Upjohn Spa | Polymeric conjugates of antitumor agents |
| GB0105929D0 (en) * | 2001-03-09 | 2001-04-25 | Btg Int Ltd | Physiologically activated prodrugs |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| US20050106100A1 (en) * | 2003-09-03 | 2005-05-19 | Harris Thomas D. | Compounds containing matrix metalloproteinase substrates and methods of their use |
| US8420603B2 (en) | 2004-05-14 | 2013-04-16 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
| CA2591914C (en) | 2005-01-24 | 2017-04-25 | Board Of Regents, The University Of Texas System | Fc-fusion constructs binding to phosphatidylserine and their therapeutic use |
| US20090022782A1 (en) | 2005-02-25 | 2009-01-22 | National University Corp. Hokkaido University | Blood Retainable Device Exhibiting Selective Degradability in Tumor Tissue |
| US7714016B2 (en) * | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| GB0707034D0 (en) | 2007-04-12 | 2007-05-23 | St Andrews The | Compounds |
| GB0819287D0 (en) | 2008-10-22 | 2008-11-26 | Univ Bradford | Compounds |
| GB2516882A (en) | 2013-08-02 | 2015-02-11 | Univ Bradford | Tumour-targeted theranostic |
-
2007
- 2007-04-12 GB GBGB0707034.5A patent/GB0707034D0/en not_active Ceased
-
2008
- 2008-03-27 WO PCT/GB2008/001043 patent/WO2008125800A2/en not_active Ceased
- 2008-03-27 EP EP08718877.7A patent/EP2134372B1/en not_active Not-in-force
- 2008-03-27 EP EP12160565.3A patent/EP2481429B1/en not_active Not-in-force
- 2008-03-27 JP JP2010502559A patent/JP5537413B2/ja not_active Expired - Fee Related
- 2008-03-27 ES ES08718877.7T patent/ES2573228T3/es active Active
- 2008-03-27 LT LTEP12160565.3T patent/LT2481429T/lt unknown
- 2008-03-27 PT PT121605653T patent/PT2481429T/pt unknown
- 2008-03-27 EP EP12160556.2A patent/EP2481428B1/en not_active Not-in-force
- 2008-03-27 PL PL12160565T patent/PL2481429T3/pl unknown
- 2008-03-27 TR TR2018/07811T patent/TR201807811T4/tr unknown
- 2008-03-27 PL PL12160556.2T patent/PL2481428T3/pl unknown
- 2008-03-27 DK DK08718877.7T patent/DK2134372T3/en active
- 2008-03-27 DK DK12160565.3T patent/DK2481429T3/en active
- 2008-03-27 SI SI200831959T patent/SI2481429T1/en unknown
- 2008-03-27 ES ES12160565.3T patent/ES2683168T3/es active Active
- 2008-03-27 US US12/595,482 patent/US8691751B2/en not_active Expired - Fee Related
- 2008-03-27 PL PL08718877.7T patent/PL2134372T3/pl unknown
- 2008-03-27 EP EP18156526.8A patent/EP3348282A1/en not_active Withdrawn
- 2008-03-27 HU HUE08718877A patent/HUE027528T2/en unknown
- 2008-03-27 DK DK12160556.2T patent/DK2481428T3/en active
- 2008-03-27 HU HUE12160556A patent/HUE029080T2/en unknown
- 2008-03-27 HU HUE12160565A patent/HUE038633T2/hu unknown
- 2008-03-27 ES ES12160556.2T patent/ES2573682T3/es active Active
-
2013
- 2013-12-17 US US14/109,333 patent/US9358303B2/en not_active Expired - Fee Related
-
2014
- 2014-04-25 JP JP2014090990A patent/JP5911908B2/ja not_active Expired - Fee Related
- 2014-04-25 JP JP2014090991A patent/JP5931952B2/ja not_active Expired - Fee Related
-
2016
- 2016-04-27 JP JP2016088836A patent/JP6170590B2/ja not_active Expired - Fee Related
- 2016-05-06 US US15/148,368 patent/US9956296B2/en not_active Expired - Fee Related
-
2018
- 2018-03-16 US US15/923,564 patent/US10556014B2/en not_active Expired - Fee Related
- 2018-06-27 CY CY20181100663T patent/CY1120368T1/el unknown
- 2018-07-05 HR HRP20181043TT patent/HRP20181043T1/hr unknown
-
2019
- 2019-01-16 HK HK19100772.3A patent/HK1258466A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Singh et al. | Minocycline and doxycycline: more than antibiotics | |
| KR101831465B1 (ko) | 단백질 결합 프로드러그를 갖는 약물 조합 | |
| ID21696A (id) | Turunan asam antranilat sebagai modulator resistensi multi obat | |
| ES2175415T3 (es) | Inhibidores de metaloproteasas matriciales basados en fosfinato. | |
| CY1114941T1 (el) | Πολυμερη βασιζομενα σε κυκλοδεξτρινη για χορηγηση των θεραπευτικων μεσων που ειναι ομοιοπολικως δεσμευμενα σε αυτα | |
| BR112023018676A2 (pt) | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco | |
| EP1183050A2 (de) | Verfahren zur herstellung einer injizierbaren arzneimittelzubereitung | |
| UA95488C2 (ru) | Концентрированный раствор метотрексата для подкожного введения | |
| CA2516056A1 (en) | Aprotinin and analogs as carriers across the blood-brain barrier | |
| WO2005028516A3 (en) | Albumin-binding derivatives of therapeutic peptides | |
| ECSP045465A (es) | Formas de dosis y composiciones para la administración osmótica de dos variables de oxicodona | |
| CA2529972A1 (en) | Polymeric conjugates for tissue activated drug delivery | |
| RU2008138560A (ru) | Улучшенные способы лечения опухолей | |
| NZ572012A (en) | Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines | |
| CY1110078T1 (el) | Παρασκευασματα με ιωδιουχο ποβιδονη για την αγωγη τραυματων | |
| TR201902884T4 (tr) | Mmp akti̇f vasküler bozucu ajanlar. | |
| IL278717B1 (en) | Starting dose of pth conjugates | |
| MX2026000307A (es) | Ligando de proteina para la activacion de fibroblastos y su uso | |
| MX2025010596A (es) | Compuestos de fármacos con una porción de unión de albúmina | |
| ME00624B (me) | Nova primjena docetaksela za liječenje hepatoma | |
| ES2377016T3 (es) | Tioridazina y derivados de la misma para invertir la resistencia a los fármacos anti-microbianos | |
| ES2317913T3 (es) | Tratamiento antitumoral combinado que comprende un derivado de la distamicina sustituida por acriloilo y un antimetabolito. | |
| Ala’Abu-Jaish et al. | Prodrug overview | |
| JP2009046450A (ja) | 抗がん剤へのヒアルロン酸添加 | |
| ES2875459T3 (es) | Complejos nanoensamblados de ácidos nucleicos, avidina y compuestos biotinilados para el uso como portadores de fármacos |